SMAD4 plays the critical intracellular signal transduction mediator in the TGF-β pathway; the protein deletion is currently associated with lymph-node metastases, increased angiogenesis in vitro, and more aggressive tumor behavior in patients [36,37]. This evidence concerns the gene TGFB1 and neoplasm.